MarketsandMarkets Conferences, Author at Blogs & Articles

BIOSIMILARS: Origins & The Path Forward

April 19, 2022August 16, 2023 MarketsandMarkets Conferences

Almost 7 years removed from the first FDA approved Biosimilar (Zarxio) in 2015, the US market for Biosimilars is projected to be highly beneficial over the next decade, for both pharmaceutical companies as well as patients, with RAND Corporation projecting estimated savings of over $54 Billion during this period. To truly comprehend such forecasts, a deeper understanding of what constitutes a ‘Biosimilar Drug’ is required. Essentially, the structure of a biosimilar is based on a pre-existing, approved drug known as a Biologic & possesses no significant clinical difference in safety,…

AI – The Future at our Doorstep

April 18, 2022 MarketsandMarkets Conferences

Artificial Intelligence has progressively transitioned from a futuristic technology expected to be decades away, to one whose usage & integration into our daily lives is growing by the minute.From quantum computing to medical diagnostics and the more prevalent trend of autonomous vehicles, AI has well and truly arrived & is here to stay. With a large stream of information flowing across the endless digital space, any effort to understand the structure, capabilities & potential benefits or disadvantages of AI is a mammoth task for a vast majority of the world….

Catch up with Matt Davis’ talk on “Neoantigen Targeted Cancer Immunotherapy in the Clinic” at Advance Genetic Sequencing Virtual Conference 2021

September 14, 2021September 20, 2021 MarketsandMarkets Conferences

Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group. He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute. Marketsandmarkets took this opportunity to talk…

Ning Wang talks about “Single cell sequencing: a powerful approach to profile tumor microenvironment” at Advance Genetic Sequencing Virtual Conference 2021

September 7, 2021September 7, 2021 MarketsandMarkets Conferences

Ning is a bioinformatics scientist at Arcus Biosciences, where he is responsible for drug discovery, target identification, and indication prioritization in multiple immune-oncology drug programs. Notably, Ning pioneered the 3D organoids based drug response prediction technology, which largely facilitated cancer model selection. During his PhD, he studied with Professor Alexander Hoffmann at UCLA, where he built up computational framework to identify synergy between key immune response signaling pathways in macrophage. Ning holds a PhD in Bioinformatics from UCLA. Marketsandmarkets took this opportunity to pick his brains on the newfound developments…

Grace Zhao, Co-founder, Avida Biomed discusses- “Dual methylation and mutation analysis from a single input of plasma cfDNA without sample splitting”

September 2, 2021 MarketsandMarkets Conferences

Grace Zhao is a co-founder of Avida Biomed, a biotech start-up specializing in genomic technology innovation for molecular diagnostics. At Avida, Grace co-invented Point-n-Seq, a new platform technology to advance liquid biopsy for early detection of cancer and other diseases. Utilizing the ultra-efficient, hybridization-based pre-amplification enrichment of target molecules from nanogram level cell free DNA (cfDNA), Point-n-Seq enables the first targeted mutation and methylation cfDNA dual analysis solution on market. Grace is currently the head of clinical research defining and executing company-wide clinical research strategy. Before Avida, Grace co-founded AccuraGen,…

An Overview of Spatial Transcriptomics: Techniques and Applications With Cátia Moutinho of GWCCG

August 18, 2021August 18, 2021 MarketsandMarkets Conferences

Dr. Cátia Moutinho is the Associate Director of Garvan-Weizmann Centre for Cellular Genomics, at the Garvan Institute Sydney-Australia. Also, she is the Group Leader of the Single Cell Technology Development Team. Her group focuses on single-cell genomics development. She is a biologist by training, with a PhD in Biomedicine and a master in Clinical Trials and Medical Affairs. She has an extensive experience in the wet-lab, with a strong background in single-cell technology, as well as cancer genetics and epigenetics. Cátia is also co-founder of the Single-Cell Ninjas Project, a…

The technology and applications of single-cell analysis have advanced dramatically in the last five years- 2nd Annual MarketsandMarkets Single-Cell Analysis Virtual Conference

July 30, 2021 MarketsandMarkets Conferences

2nd Annual MarketsandMarkets Single-Cell Analysis Virtual Conference to be held on 9th – 10th November 2021 will host industry giants like San Diego Nanotechnology Infrastructure, CHDI Foundation, Brigham Young University, AbSci, Stowers Institute for Medical Research, University of Florence, Pfizer, l’Université et CHU de Montpellier and many more. The single-cell analysis market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% during the forecast period. The growth in this market is driven by technological advancements in single-cell analysis products,…

Multiple factors & challenges preventing cell and gene therapies to be widely used- 3rd Annual MarketsandMarkets Cell & Gene Therapy Manufacturing Virtual Conference

July 30, 2021July 30, 2021 MarketsandMarkets Conferences

3rd Annual MarketsandMarkets Cell & Gene Therapy Manufacturing Virtual Conference to be held on 28th – 29th October 2021 will host industry giants like Advanced Cell & Gene Therapy LLC, Cell & Gene Therapy Consulting LLC, panCella, Sigilon Inc, Biotechnology Biopharmaceuticals and many more. The global cell & gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7 billion in 2021, at a CAGR of 12.4% during the forecast period. Growth in this market is primarily driven by the high incidence of…

Real World Evidence is key for pharma organizations in drug development- 5th Edition MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference

July 30, 2021July 30, 2021 MarketsandMarkets Conferences

5th Edition MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference (Time Zone – EST) to be held on 19th – 22nd October 2021 will host industry giants like Sarepta Therapeutics, Idorsia Pharmaceuticals, Food and Drug Administration (FDA), AveXis, Rafael Pharmaceuticals, PicnicHealth, Dedalus Group, RTI Health Solutions, Bluebird Bio, Seagen, Takeda, Takeda Pharmaceuticals, Novartis, OM1 and many more. The global real-world evidence market is valued at 612.0 million in 2017 and projected to reach USD 1,348.1 million by 2023, at a CAGR of 14.3%. The growth of this…

Discovering the future of infection prevention and control – 6th Edition Infection Control, Sterilization & Decontamination Virtual Conference 2021

July 15, 2021 MarketsandMarkets Conferences

July 12th, 2021- Following up the legacy of 5 very successful annuals in UK & Europe geographies, we are proud to to announce the 6th Edition Infection Control, Sterilization & Decontamination Virtual Conference, Middle East, scheduled for 5th-6th October, 2021. This edition will focus on key topics like the utilization of reprocessed equipment to disinfect or sterilize medical devices, decontamination of surgical instruments, endoscopic devices, respiratory care devices, and reusable hemodialysis machines. How Patient-to-patient pathogen transmission via medical devices can be entirely prevented by properly sterilising medical devices. These topics…